EUCTR2009-011663-37-GB进行中（未招募）不适用
Multicentre, randomized, double-blind, active comparator-and placebo-controlled, parallel-group phase III clinical study for the evaluation of Diclofenac HPBCD 25, 50 mg/ml administered as a single s.c. dose, in the treatment of acute moderate-to-severe post-surgical pain from dental surgery (impacted 3rd molar extraction)
IBSA, Institut Biochimique SA0 个研究点目标入组 300 人开始时间: 2009年5月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Out-patients of both genders.
- •2.Patients aged = 18 to = 65 years old.
- •3.Subjects able and willing to give their written consent prior to inclusion in the study.
- •4.Female subjects of childbearing potential must have a negative urine pregnancy test at screening and inclusion visit (i.e. not status post hysterectomy or tubal ligation) must be using an appropriate method of contraception according to the definition of Note of ICH M3 Guideline (implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence of vasectomised partner) and must be willing to continue using it throughout the entire study period.
- •5.Subjects must be able to comprehend the full nature and purpose of the study, including possible risks and side effects, to co-operate with the Investigator, to comply with the requirements of the entire study and to return for the required examinations.
- •Trial specific
- •6.Patients undergoing surgical extraction of a single fully or partially impacted mandibular 3rd molar requiring bone removal.
- •7.Patients experiencing moderate to severe post-operative pain, defined as a pain intensity = 50 mm (VAS), within 6 hours from end of surgery.
- •8.Pre-operative laboratory tests (haematology, blood chemistry, urinalysis), performed within 30 days before inclusion (Visit 1) in the reference ranges or without clinically significant abnormalities as judged by the Investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients refusing to give a written informed consent.
- •2.Patients not able to understand the purposes of the study.
- •3.Patients not reliable, according to the investigator’s opinion.
- •4.Patients with major psychiatric disorders that could compromise the patient’s participation in the study.
- •5.Patients previously enrolled in this study or having used any investigational drug/device or participated in any clinical trial in the previous 3 months.
- •6.Employees of the Investigator or study centre (i.e. Principal Investigator, sub-investigator, study coordinators, other study staff, employees, or contractors of each), with direct involvement in the proposed study or other studies under the direction of that investigator and/or study centre, as well as family members of the employees or investigator.
- •7.Pregnant or breast-feeding women.
- •8.Alcohol or drug abuse within previous 12 months.
- •9.Clinically significant or unstable concurrent diseases whose sequeleae or treatment might interfere with the study evaluation parameters.
- •Trial specific
- •10.Contra-lateral lower 3rd molar extraction or any other concomitant extraction.
- •11.Surgery performed under general anaesthesia, or sedation (including nitrous oxide by inhalation).
- •12.Complications occurring during the surgical procedure or in the period before randomisation as judged by the investigator.
- •13.Acute local or systemic infection at the time of surgery that could confound the post-surgical evaluation.
- •14.Patients with clinical signs of gastritis, gastro-duodenal ulcer, GI bleeding. Other GI disturbances or disease that in the opinion of the investigator could be negatively affected by the administration of NSAIDs.
- •15.Clinical signs or history of coagulation disorders that could be negatively affected by NSAIDs administration.
- •16.Hepatic or renal impairment.
- •17.Patients with significant cardiac impairment (i.e. severe heart failure, severe ischemic heart disease) history of cerebrovascular disease (i.e. ictus), history or peripheral arterial disease, uncontrolled hypertension, (i.e. not stable = repeated measurements of systolic pressure > 160 mm Hg or diastolic pressure > 95 mm Hg, despite pharmacological treatment).
- •18.Hypersensitivity to diclofenac or other NSAIDs or to one of the study medication components.
- •19.Patients under chronic treatment with topical or systemic analgesics/NSAIDs.
- •Non-permitted medications
- •20.Patients under treatment with any medication reported in the table below:
- •Non-permitted medications Period of wash-out before surgery
- •Systemic NSAIDs or analgesics24 hours
- •Long acting aspirin24 hours
- •Long-acting NSAIDs7 days
- •Opioids7 days
- •Major or minor tranquillizers*24 hours
- •Muscle relaxant24 hours
- •Antihistaminesº24 hours
- •MAO inhibitors2 weeks
- •Other antidepressant: SSRI, serotonin/norepinephrine reuptake inhibitors, and triciclics.3 weeks
- •Corticosteroids
- •(by any route of administration)60 days
- •*Benzodiazepine-type anxiolytics with analgesic or muscle relaxant effect are allowed if their use had been started at least 6 months earlier for other medical reasons: in this latter case, their dose must be maintained unchanged throughout the whole trial period
- •ºUnless their use had been started at least 6 months earlier for other medical reasons: in this latter case, their dose must be maintained unchanged throughout the whole trial period
- •21.Patients under treatment with any medication whose concomitant use may be susceptible to intera
研究者
相似试验
招募中
不适用
a Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase ? Study to Evaluate the Efficacy and Safety of HL151 versus Talion Tab. in Pruritus cutaneus.Diseases of the skin and subcutaneous tissueKCT0003936Hanlim Pharmaceutical196
招募中
不适用
Multi-center, Randomized, Double-blinded, Active-controlled, 12-weeks, Non-inferiority phase 3 trial to Evaluate the Efficacy and Safety of IMD-Omega Soft Cap. in the complex (IIb) patients with hypertriglyceridemia and hypercholesterolemiaEndocrine, nutritional and metabolic diseasesKCT0009700IMDPharm240
进行中（未招募）
不适用
Trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone, tretinoin gel alone, and vehicle in the treatment of acne vulgaris in patients from 12 to less than 18 years of age.Treatment of acne vulgarisMedDRA version: 14.1Level: HLTClassification code 10000497Term: AcnesSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-022918-15-Outside-EU/EEADow Pharmaceutical Sciences1,288
进行中（未招募）
1 期
A multi-centre, randomized, double-blind, active control, parallel-group, 2-arm study to investigate the effect of ethinylestradiol / drospirenone / (0.02 mg/3 mg) oral contraception in a 24/4 regimen compared to ethinylestradiol / desogestrel (0.02 mg/0.15 mg) oral contraception in a 21/7 regimen on hormone withdrawal associated symptoms in otherwise healthy women after 4 cycles of treatment - Comparative trial in hormone withdrawal associated symptomsOral ContraceptionMedDRA version: 12.0Level: LLTClassification code 10030970Term: Oral contraceptionEUCTR2009-014911-11-GBBayer HealthCare AG
进行中（未招募）
不适用
A multi-centre, randomized, double-blind, active control, parallel-group, 2-arm study to investigate the effect of ethinylestradiol / drospirenone / (0.02 mg/3 mg) oral contraception in a 24/4 regimen compared to ethinylestradiol / desogestrel (0.02 mg/0.15 mg) oral contraception in a 21/7 regimen on hormone withdrawal associated symptoms in otherwise healthy women after 4 cycles of treatment. - Comparative trial in hormone withdrawal associated symptomsOral contraceptionMedDRA version: 9.1Level: PTClassification code 10030970EUCTR2009-014911-11-ITBayer Healthcare AG680